Wall Street Zen upgraded shares of Entero Therapeutics (NASDAQ:GRDX – Free Report) from a strong sell rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.
Entero Therapeutics Price Performance
GRDX opened at $4.92 on Friday. The company has a market capitalization of $35.08 million, a price-to-earnings ratio of -2.59 and a beta of 1.67. The firm’s fifty day moving average price is $4.11 and its two-hundred day moving average price is $3.58. Entero Therapeutics has a 1 year low of $1.87 and a 1 year high of $6.93.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for gastrointestinal diseases. The company’s research programs are designed to address conditions involving intestinal inflammation, gluten intolerance and digestive enzyme deficiencies.
Its pipeline has included latiglutenase, an oral enzyme therapy being developed for celiac disease, as well as niclosamide-based therapies for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.
Further Reading
- Five stocks we like better than Entero Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
